I love how a statement from the FDA basically saying "you can use your $500M worth of old data" isn't price sensitive for a $360M market cap company! And the FDA gave guidance on what sort of AML they want us to look at.
Starting valuation has got to be $500M for data, plus $5B for AML (benchmark historic transactions support this), plus same again for each of FTO and cardio-protection (because they are massive opportunities but currently unproven).
Once proven, I don't think $20B will cut it
Ann: Positive Pre-IND Guidance from FDA on Zantrene, page-12
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |